PTC Therapeutics, Inc. (PTCT)

NASDAQ: PTCT · Real-Time Price · USD
51.87
+0.61 (1.19%)
At close: Jun 16, 2025, 4:00 PM
51.62
-0.25 (-0.48%)
After-hours: Jun 16, 2025, 5:38 PM EDT
1.19%
Market Cap 4.11B
Revenue (ttm) 1.77B
Net Income (ttm) 594.84M
Shares Out 79.26M
EPS (ttm) 7.51
PE Ratio 6.91
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 932,568
Open 51.04
Previous Close 51.26
Day's Range 49.86 - 51.95
52-Week Range 28.72 - 58.38
Beta 0.51
Analysts Buy
Price Target 62.31 (+20.13%)
Earnings Date Aug 7, 2025

About PTCT

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. I... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 20, 2013
Employees 939
Stock Exchange NASDAQ
Ticker Symbol PTCT
Full Company Profile

Financial Performance

In 2024, PTC Therapeutics's revenue was $806.78 million, a decrease of -13.97% compared to the previous year's $937.82 million. Losses were -$363.30 million, -42.02% less than in 2023.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for PTCT stock is "Buy." The 12-month stock price forecast is $62.31, which is an increase of 20.13% from the latest price.

Price Target
$62.31
(20.13% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against PTC Therapeutics, Inc. (PTCT) And Encourages Shareholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NA...

26 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against PTC Therapeutics, Inc. (PTCT) and Encourages Shareholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NA...

27 days ago - Accesswire

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NA...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages PTC Therapeutics, Inc. (PTCT) Shareholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NA...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeutics, Inc. (PTCT) And Encourages Investors to Connect

NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NA...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages PTC Therapeutics, Inc. (PTCT) Stockholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NA...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against PTC Therapeutics, Inc. (PTCT) and Encourages Investors to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NA...

4 weeks ago - Accesswire

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NA...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeutics, Inc. (PTCT) And Encourages Stockholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NA...

5 weeks ago - Accesswire

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NAS...

5 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against PTC Therapeutics, Inc. (PTCT) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NAS...

5 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages PTC Therapeutics, Inc. (PTCT) Investors to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NAS...

5 weeks ago - Accesswire

PTC Therapeutics, Inc. (PTCT) Q1 2025 Earnings Call Transcript

PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2025 Earnings Call May 6, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Head, Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels -...

5 weeks ago - Seeking Alpha

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

– Strong revenue performance of $190 million –  – Positive CHMP opinion for Sephience™  (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date –  – Global Sephi...

5 weeks ago - PRNewsWire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against PTC Therapeutics, Inc. (PTCT) And Encourages Investors to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / May 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NAS...

5 weeks ago - Accesswire

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?

PTC Therapeutics, Inc. PTCT on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.

6 weeks ago - Benzinga

PTC518 PIVOT-HD Study Achieves Primary Endpoint

- Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 - - Favorable dose-dependent trends across clinical scales in Stage 2 patients at Month 12 - - Signals of dose-de...

6 weeks ago - PRNewsWire

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J. , May 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that on April 25, 2025, the company approved non-statutory stock options to purchase an aggregate of 7,...

6 weeks ago - PRNewsWire

PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

- Label includes full spectrum of PKU patients - - European launch preparations underway - WARREN, N.J. , April 25, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the ...

7 weeks ago - PRNewsWire

PTC Therapeutics to Participate at Upcoming Investor Conferences

WARREN, N.J. , April 24, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Bank of America Securities 2025 Health ...

7 weeks ago - PRNewsWire

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

WARREN, N.J. , April 17, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2025 financial resu...

2 months ago - PRNewsWire

Vaccine stocks fall following FDA resignation

Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.

Other symbols: BNTXMRNANVAXPFEPCVXXBI
2 months ago - CNBC Television

PTC Therapeutics Shares Fall After EU Drops Translarna Authorization

Shares of PTC Therapeutics fell after the company said regulators for the European Union won't renew authorization for its Translarna treatment for nonsense mutation Duchenne muscular dystrophy.

2 months ago - Market Watch

PTC Therapeutics says European Commission will remove muscle disorder drug

PTC Therapeutics said on Friday the European Commission will remove its inherited progressive muscle-wasting disorder from the region after an advisory panel reaffirmed a negative opinion of the drug ...

2 months ago - Reuters

PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe

WARREN, N.J. , March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products fo...

2 months ago - PRNewsWire